Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 10, 2011

Amylin Allies with JDRF to Evaluate Co-Formulation of Symlin with Insulin

  • Amylin Pharmaceuticals and the Juvenile Diabetes Research Foundation (JDRF) inked a research collaboration to fund a series of clinical studies evaluating the potential to co-formulate Amylin’s injectable pramlintide drug Symlin® with insulin for the treatment of type 1 diabetes.

    Symlin is an analogue of the human hormone amylin and is approved for use as an adjunct to mealtime insulin therapy in patients who can’t achieve desired glucose control using optimum insulin. However, at present the two drugs need to be administered as separate injections and can’t be mixed.

    The collaboration between JDRF and Amylin will involve up to three clinical proof-of-concept trials to evaluate whether a fixed ratio of pramlintide and insulin can effectively control glucose levels and identify the optimal dose ratios. JDRF and Amylin point out that in addition to simplifying treatment, a single injection combining pramlintide and insulin may better mimic the natural physiology of the pancreas.

    The two organizations have a separate, ongoing collaboration to carry out a proof-of-concept study evaluating the human leptin analog metreleptin in patients with type 1 diabetes.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »